Two Sigma Securities’s Galectin Therapeutics GALT Stock Holding History

Two Sigma Securities’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,571	Closed	-$36.9K	–	1709
2024 Q4	$36.9K	Buy	+28,571	New	+$68.5K	﹤0.01%	1226
2022 Q4	–	Sell	-13,384	Closed	-$22K	–	2813
2022 Q3	$22K	Buy	+13,384	New	+$25K	﹤0.01%	2289
2017 Q2	–	Sell	-15,243	Closed	-$35K	–	976
2017 Q1	$35K	Buy	+15,243	New	+$23K	0.01%	824
2016 Q4	–	Sell	-15,429	Closed	-$17K	–	793
2016 Q3	$17K	Buy	+15,429	New	+$27.4K	0.01%	611

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Two Sigma Securities's GALT Position: Q1 2025 in Review

Two Sigma Securities sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 28,571 shares — an estimated $36.9K sold.

Two Sigma Securities first reported a position in GALT in Q3 2016 and held it in 4 quarters. The position peaked at $36.9K in Q4 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

Two Sigma Securities reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
Two Sigma Securities sold 28,571 Galectin Therapeutics shares in Q1 2025, an estimated $36.9K.
Two Sigma Securities first reported a position in Galectin Therapeutics in Q3 2016 and held it in 4 quarters.
Two Sigma Securities's Galectin Therapeutics position peaked at $36.9K in Q4 2024.
93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.